Company Information

  

Address: 300 AMERICAN RD  
City: MORRIS PLAINS 
State: NJ 
Zip Code: 07950 
Telephone: 973-605-8200 

Description of Business

Primary SIC Code: 2835
(As filed with the SEC)  

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Our proprietary technologies allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, we have built a pipeline of six clinical-stage product candidates. Our most advanced product candidate is IMMU-132 (sacituzumab govitecan), an antibody-drug conjugate ("ADC") that has received Breakthrough Therapy Designation ("BTD") from the United States Food and Drug Administration ("FDA") for the treatment of patients with metastatic triple-negative breast cancer ("mTNBC") who have failed at least two prior therapies for metastatic disease.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-2.27NAN/E
06/2017-1.47NAN/E
03/2017-1.13NAN/E
12/2016-0.72NAN/E
09/2016-0.63NAN/E
06/2016-0.62NAN/E
03/2016-0.59NAN/E
12/2015-0.56NAN/E

Key Financial Ratios and Statistics

FYE: 06/30

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.33Total Liab/Total Assets1.36
Net Inc/Total Assets-0.94Total Liab/Inv Cap5.49
Net Inc/Inv Cap-3.80Total Liab/Comm Equity0.48
Pretax Inc/Net Sales-49.57Interest Coverage Ratio-26.97
Net Inc/Net Sales-49.56Curr Debt/EquityNA
Cash Flow/Net Sales-20.14LTD/Equity-1.67
SG&A/NetSales9.70Total Debt/Equity-1.67
Asset Utilization   Liquidity  
Net Receivables Turnover4.93Quick Ratio1.28
Inventory Turnover1.04Current Ratio1.29
Inventory Day Sales0.00Net Rec/Curr Assets0.00
Net Sales/Work Cap0.09Inv/Curr Assets0.00
Net Sales/PP&E0.59  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 0.69 0.64 1.32 0.38
Cost of Goods Sold 0.07 0.05 0.14 0.05
Selling & Admin Exps 4.88 15.31 10.82 2.95
Operating Income -21.60 -26.72 -22.12 -15.36
Interest Exp 2.65 1.37 1.37 1.37
Pretax Income -118.76 -53.25 -59.32 -24.45
Other Income -94.52 -25.15 -35.83 -7.72
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -118.74 -53.25 -59.31 -24.45

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 139.63 154.90 45.97 46.61
Receivables - Total 0.45 0.50 0.93 0.19
Inventories - Total 0.53 0.58 0.69 0.74
Total Current Assets 147.36 157.30 48.49 48.82
Net Property, Plant & Equipment 5.97 5.25 4.17 4.28
Total Assets 153.36 162.57 52.69 53.12
Liabilities        
Accounts Payable 33.40 31.37 19.60 14.10
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 199.39 122.24 84.99 28.86
Long-Term Debt 19.65 98.08 97.90 97.72
Total Liabilities 219.96 221.27 183.85 127.56
Stockholder's Equity        
Minority Interest -0.79 -0.77 -0.76 -0.74
Preferred Stock 0.00 0.01 0.00 0.00
Common Stock 1.52 1.10 1.10 1.06
Retained Earnings -640.46 -521.71 -468.46 -409.15
Treasury Stock -0.46 -0.46 -0.46 -0.46
Total Stockholders' Equity -66.60 -58.69 -131.16 -74.44
Total Liabilities and Stockholders' Equity 153.36 162.57 52.69 53.12

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -20.57 -14.06 -16.68 -14.70
Net Cash Provided by Investing Activities 14.09 -88.51 17.39 -17.21
Net Cash Provided by Financing Activities 6.05 124.16 16.15 28.49

Annual Summary Data (Millions)

Year Sales Net Income EPS
06/20134.96-11.38-0.16
06/20149.04-35.43-0.42
06/20155.65-48.00-0.51
06/20163.23-59.04-0.62
06/20173.09-153.21-1.47
Growth Rates-11.16----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17165115,99676.30




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.